CD8A and neoplasm: Importantly, the anti-tumour activity of PARPi in tumour-bearing mice is impaired by CD8+ T-cell depletion, or by neutralization with an anti-CD8 antibody [34,35], suggesting that the adaptive immune system also plays a role in PARPi efficacy.